



PATENT
Customer No. 22,852
Attorney Docket No. 02481.1834-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Swen HÖLDER et al.) Group Art Unit: 1624
)
Application No.: 10/715,358) Examiner: Kahsay HABTE
)
Filed: November 19, 2003) Confirmation No.: 3767
)
For: NOVEL PYRIDAZINONE DERIVATIVES)
AS PHARMACEUTICALS AND)
PHARMACEUTICAL COMPOSITIONS)
CONTAINING THEM)

MAIL STOP RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TERMINAL DISCLAIMER

Assignee, Sanofi-Aventis Deutschland GmbH, whose predecessor is Aventis
Pharma Deutschland GmbH, duly organized under the laws of Germany and having its
principal place of business at Industrial Park Höchst, Building K 801, D65926, Frankfurt
am Main, Germany, through its attorneys, represents that it is the assignee of the entire
right, title, and interest in and to the instant application, Application No. 10/715,358 filed
November 19, 2003, for NOVEL PYRIDAZINONE DERIVATIVES AS
PHARMACEUTICALS AND PHARMACEUTICAL COMPOSITIONS CONTAINING
THEM in the names of Swen HÖLDER, Thorsten NAUMANN, Karl SCHÖNAFINGER,
David William WILL, Hans MATTER, Günther MÜLLER, Dominique Le SUISSE,

Bernard BAUDOIN, Thomas ROONEY, Franck HALLEY, and Gilles TIRABOSCHI, as indicated by executed Assignment recorded on May 19, 2004, at Reel 016057, Frame 0951 and Change of Name from Aventis Pharma Deutschland GmbH to Sanofi-Aventis Deutschland GmbH recorded on November 17, 2005, at Real 017032, Frame 0754.

Assignee, Sanofi-Aventis Deutschland GmbH, further represents, through its attorneys, that it is the assignee of the entire right, title, and interest in and to co-pending Application No. 10/715,556 ("the '556 application"), filed November 19, 2003, for NOVEL PYRIDAZINONE DERIVATIVES AS PHARMACEUTICALS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM in the names of Swen HÖLDER, Thorsten NAUMANN, Karl SCHÖNAFINGER, David William WILL, Hans MATTER, Günther MÜLLER, Dominique Le SUISSE, Bernard BAUDOIN, Thomas ROONEY, Franck HALLEY, Gilles TIRABOSCHI, Cécile COMBEAU, Ingrid SASSOON, and Anke STEINMETZ, as indicated by executed Assignment recorded on September 16, 2004, at Reel 015791, Frame 0542 and Change of Name from Aventis Pharma Deutschland GmbH to Sanofi-Aventis Deutschland GmbH recorded on February 13, 2006, at Real 017256, Frame 0687.

To obviate a double patenting rejection, Assignee hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156 and 173, as presently shortened by any terminal disclaimer, of any patent granted on the '556 application. Assignee hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the '556 application are

commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, Assignee does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of any patent granted on the '556 application, as presently shortened by any terminal disclaimer, in the event that any patent granted on the '556 application later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or in part, is terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

In accordance with the fee schedule set forth in 37 C.F.R. § 1.20(d), the required fee of \$130.00 is being filed with this disclaimer.


If a check for the required fee is not filed concurrently herewith or if there are any additional fees due in connection with the filing of this Terminal Disclaimer, please charge the fees to our Deposit Account No. 06-0916. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to Deposit Account No. 06-0916

The undersigned is an attorney of record.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

DATE: February 6, 2007

BY: 
Bryan C. Diner
Reg. No. 32,409